Form 4: Apyx Medical Corp Director Lawrence Waldman Acquires Stock Options
SEC Form 4 Filing
Director Lawrence Waldman acquired 50,000 stock options in Apyx Medical Corp on January 15, 2025, as part of the Director Compensation Program.
Summary
- Lawrence Waldman, a director of Apyx Medical Corp, reported a transaction on January 15, 2025.
- Waldman acquired 50,000 stock options with an exercise price of $1.42.
- These options were issued under the Issuer's Director Compensation Program.
- The options vest ratably over 12 months and become fully vested on the first anniversary of the grant date.
- The options expire on January 15, 2035.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of director compensation.
Industry Context
This filing is a routine disclosure of insider transactions, specifically the granting of stock options to a director, which is a common practice in corporate governance to align the interests of directors with those of shareholders.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 01/15/2025 | Date of transaction: Lawrence Waldman acquired stock options. |
| 01/17/2025 | Date of signature on the Form 4 filing. |
| 01/15/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.